MedTrace Logo

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

NCT00492726 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 804

Last updated 2014-11-07

Study results available
· View outcomes & findings →

Summary

A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.

Conditions

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

Moxifloxacin, 400mg, administered intravenously once daily

DRUG

Ertapenem intravenous

Active treatment: Ertapenem 1.0g, administered intravenously once daily

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Argentina
  • Belgium
  • Bulgaria
  • Estonia
  • France
  • Germany
  • Greece
  • Israel
  • Latvia
  • Lithuania
  • Romania
  • Russia
  • South Africa
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00492726 on ClinicalTrials.gov